Pan-tumor zwitterionic radiopharma platform designed to prevent tumor regrowth and resistance while minimizing collateral damage to healthy tissue; lead program is a zwitterionic targeted alpha therapy focused on challenging rare cancers. Developing image-guided surgical agents, including a late-stage ureter imaging drug currently in a pivotal trial.